Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels

Life Sciences

Volumn 79, Issue 24, 2006, Pages 2269-2274

  Dairam, A ^a   Antunes, E M ^a   Saravanan, K S ^b   Daya, S ^a  

^a RHODES UNIVERSITY   (South Africa)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Dopamine; Melatonin; NSAIDS; Parkinson's disease; Serotonin; Sulindac; Tolmetin; Tryptophan 2,3 dioxygenase

Indexed keywords

DOPAMINE; MELATONIN; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN; SULINDAC; TOLMETIN; TRYPTOPHAN 2,3 DIOXYGENASE;

ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LIVER; MALE; NONHUMAN; PARKINSON DISEASE; PINEAL BODY; RAT; SEROTONIN BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; ENZYME INHIBITORS; HIPPOCAMPUS; LIVER; MALE; MELATONIN; PINEAL GLAND; RATS; RATS, WISTAR; SEROTONIN; SULINDAC; TOLMETIN; TRYPTOPHAN OXYGENASE;

EID: 33750494915     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.07.028     Document Type: Article

References (55)

1. Albin R.L., Young A., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends in Neurosciences 12 (1989) 366-375
2. Badawy A.A.B., and Evans M. The regulation of rat liver tryptophan pyrrolase by its cofactor haem. Experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms. Biochemical Journal 150 (1975) 511-520
3. Bensinger R.E., Klein D.C., Weller J.L., and Lovenberg W. Radiometric assay of total tryptophan hydroxylation by intact cultured pineal glands. Journal of Neurochemistry 23 (1974) 111-117
4. Butterweck V., Bockers T., Korte B., Bittkowski W., and Winterhoff H. Long-term effects of St. John's wort and hypericin on monoaminelevels in rat hypothalamus and hippocampus. Brain Research 930 (2002) 21-29
5. Cardinali D.P., Ritta N.M., Speziale N., and Gimeno M.F. Release and specific binding of prostaglandins in bovine pineal glands. Prostaglandins 18 (1979) 577-580
6. Cardinali D.P., Ritta N.M., Pereyra E., and Solveyra C.G. Role of prostaglandins in rat pineal neuroeffector junction. Changes in melatonin and norepinephrine release in vitro. Endocrinology 111 (1982) 530-534
7. Castano A., Herrera A.J., Cano J., and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry 70 (1998) 1584-1592
8. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 15 (2002) 991-998
9. Costa E.J., Lopes R.H., and Lamy-Freund M.T. Permeability of pure lipid bilayers to melatonin. Journal of Pineal Research 19 (1995) 123-126
10. Curzon G. Tryptophan pyrrolase-a biochemical factor in depressive illness?. British Journal of Psychiatry 115 (1969) 1367-1374
11. Curzon G., and Bridges P.K. Tryptophan metabolism in depression. Journal of Neurology, Neurosurgery and Psychiatry 33 (1970) 698-704
12. Daya S., Nonaka K.O., Buzzel G.R., and Reiter J.R. Heme precursor 5-aminolevulinic acid alters brain tryptophan and serotonin levels without changing pineal serotonin and melatonin concentrations. Journal of Neuroscience Research 23 (1989) 304-309
13. Deguchi T., and Barchas J. Effect of chlorophenylalanine or hydroxylation of tryptophan in pineal and brain of rats. Molecular Pharmacology 8 (1972) 770-779
14. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Experimental Neurology 175 (2002) 303-317
15. Flower R.J., and Vane J.R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240 (1972) 410-411
16. Greengard P., Allen A.C., and Narin A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphase-1 cascade. Neuron 23 (1999) 435-447
17. Hardeland R. New actions of melatonin and their relevance to biometeorology. International Journal of Biometeorology 41 (1997) 47-57
18. Hardeland R., and Rensing L. Circadian oscillation in rat liver tryptophan pyrrolase and its analysis by substrate and hormone induction. Nature 219 154 (1968) 619-621
19. Hardeland R., Balzer I., Poeggeler B., Fuhrber B., Uria H., Behrmann G., Wolf R., Meyer T.J., and Reiter R.J. On the primary functioning of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. Journal of Pineal Research 186 (1995) 104-111
20. Hayaishi O. In: Hyaishi O., Ishimura Y., and Kideo R. (Eds). Biochemical and Medical Aspects of Tryptophan Metabolism (1980), Elservier/North-Holland, Amsterdam 15-30
21. Kalivas P.W., and Stewart. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research Reviews 16 (1991) 223-244
22. Kema I.P., de Vries E.G., and Muskiet F.A. Clinical chemistry of serotonin and metabolites. Journal of Chromatography. B, Biomedical Sciences and Applications 74 (2000) 33-48
23. Klein D.C., Coon S.L., Roseboom P.H., Weller J.L., Bernard M., Gastel J.A., Zatz M., Luvone P.M., Rodigues I.R., Begay V., Falcon J., Cahill G., Cassone V.M., and Baler R. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Progress in Hormone Research 52 (1997) 307-357
24. Knable M.B., and Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. Journal of Psychopharmacology 11 (1997) 123-131
25. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends in Pharmacology 13 (1992) 177-184
26. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (1997) 52-58
27. Langston J.W., Forno L.S., Tetrug J., Reeves A.G., Kaplan J.A., and Karlak D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine exposure. Annals of Neurology 46 (1999) 598-605
28. Lovenberg W., Jequier E., and Sjoerdsma A. Tryptophan hydroxylation in mammalian systems. Advances in Pharmacology 6 (1968) 21-36
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193 (1951) 265-275
30. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
31. Mohanakumar K.P., Mohanty S., and Ganguly D.K. Single neonatal administration of serotonin antiserum inhibits serotonin metabolism and function in adult rats. NeuroReport 7 (1995) 238-240
32. Mohanakumar K.P., Muralikrishnan D., and Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Research 864 (2000) 281-290
33. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB 12 (1998) 905-912
34. Murphy P.J., Myers B.L., and Badia P. Nonsteroidal anti-inflammatory drugs alters body temperature and suppress melatonin in humans. Physiology and Behavior 69 (1986) 133-139
35. Musajo L., and Benassi C.A. Aspects of disorders of the kynurenine pathway of tryptophan metabolism in man. Advances in Clinical Chemistry 7 (1964) 63-135
36. Nestler E.J., and Aghajanian G.K. Molecular and cellular basis of addiction. Science 278 (1997) 58-63
37. Price J.M., Brown R.R., and Yess N. Testing the functional capacity of the tryptophan-niacin pathway in man by analysis of urinary metabolites. Advances in Metabolic Disorders 2 (1965) 159-225
38. Reiter R.J. Melatonin: that ubiquitously acting pineal hormone. News in Physiological Sciences 6 (1991) 223-227
39. Reiter R.J. The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Neurochemistry International 27 (1995) 453-460
40. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Progress in Neurobiology 56 (1998) 359-384
41. Reiter R.J., Melchiorri D., Sewerynek E., Poeggler B., Barlow-Walden L., Chuang J., Ortiz G.G., and Acuna-Casttroviejo D. A review of the evidence supporting melatonin's role as an antioxidant. Journal of Pineal Research 18 (1995) 1-11
42. Reiter R.J., Guerrero J.M., Escames G., Pappolla M.A., and Acuna-Castroviejo D. Prophylactic actions of melatonin in oxidative neurotoxicity. Annals of the New York Academy of Sciences 825 (1997) 70-78
43. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Research 966 (2003) 245-252
44. Shida C.S., Castrucci A.M., and Lamy-Freund M.T. High melatonin solubility in aqueous medium. Journal of Pineal Research 16 (1994) 198-201
45. Surrall K., Smith J.A., Bird H., Okala B., Othman H., and Padwick D.J. Effect of ibuprofen and indomethacin on human plasma melatonin. Journal of Pharmacy and Pharmacology 39 (1987) 840-843
46. Szelenyi J., and Selmeczy Z. Immunomodulatory effect of antidepressants. Current Opinion in Pharmacology 2 (2002) 428-432
47. Tan D.X., Chen L.D., Poeggler B., Manchester L.C., and Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine Journal 1 (1993) 57-60
48. van Praag H.M. Depression, suicide and the metabolism of serotonin in the brain. Journal of Affective Disorders 4 (1982) 275-290
49. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. New Biology 234 (1971) 231-238
50. Voisin P., Van Camp G., Pontoire C., and Collin J.P. Prostaglandins stimulate serotonin acetylation in chick pineal cells: involvement of cyclic AMP-dependent and calcium/calmodulin-dependent mechanisms. Journal of Neurochemistry 60 (1993) 666-670
51. Walsh H.A., and Daya S. Influence of the antidepressants desipramine and fluoxetine on tryptophan-2,3-dioxygenase in the presence of exogenous melatonin. Life Sciences 62 (1998) 2417-2423
52. Williams G.V., and Goldman-Rakic P.S. Modulation of memory fields by D1 receptors in prefrontal cortex. Nature 376 (1995) 572-575
53. Wolf H. Studies on tryptophan metabolism in man. Scandinavian Journal of Clinical and Laboratory Investigation. Supplement 136 (1974) 1-186
54. Xie F., Wong P., Yoshioka K., Cooks R.G., and Kissinger P.T. Journal of Liquid Chromatography and Related Technologies 21 (1998) 1273
55. Zar J.H. Biostatistical Analysis (1974), Prentice Hall, Engelwood Cliffs, NJ 151-466